Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 2
2013 1
2014 1
2015 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease.
Sibley CH, Chioato A, Felix S, Colin L, Chakraborty A, Plass N, Rodriguez-Smith J, Brewer C, King K, Zalewski C, Kim HJ, Bishop R, Abrams K, Stone D, Chapelle D, Kost B, Snyder C, Butman JA, Wesley R, Goldbach-Mansky R. Sibley CH, et al. Among authors: chioato a. Ann Rheum Dis. 2015 Sep;74(9):1714-9. doi: 10.1136/annrheumdis-2013-204877. Epub 2014 Jun 6. Ann Rheum Dis. 2015. PMID: 24906637 Free PMC article. Clinical Trial.
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.
Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, Bader-Meunier B, Vastert SJ, Noseda E, D'Ambrosio D, Lecot J, Chakraborty A, Martini A, Chioato A; Paediatric Rheumatology International Clinical Trials Organisation. Ruperto N, et al. Among authors: chioato a. Arthritis Rheum. 2012 Feb;64(2):557-67. doi: 10.1002/art.33342. Arthritis Rheum. 2012. PMID: 21953497 Free article. Clinical Trial.
Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study.
Chioato A, Noseda E, Stevens M, Gaitatzis N, Kleinschmidt A, Picaud H. Chioato A, et al. Clin Vaccine Immunol. 2012 Oct;19(10):1597-602. doi: 10.1128/CVI.00386-12. Epub 2012 Aug 8. Clin Vaccine Immunol. 2012. PMID: 22875601 Free PMC article. Clinical Trial.
Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study.
Chioato A, Noseda E, Felix SD, Stevens M, Del Giudice G, Fitoussi S, Kleinschmidt A. Chioato A, et al. Clin Vaccine Immunol. 2010 Dec;17(12):1952-7. doi: 10.1128/CVI.00175-10. Epub 2010 Oct 20. Clin Vaccine Immunol. 2010. PMID: 20962212 Free PMC article. Clinical Trial.